Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling of Serum M-Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Clinical and translational science
Published: March 19, 2025
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
Journal: Blood
Published: July 17, 2024
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Journal: American journal of hematology
Published: November 08, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Journal: Blood cancer journal
Published: September 02, 2022
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Journal: Annals of hematology
Published: October 27, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
Journal: Leukemia
Published: December 19, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Journal: European journal of haematology
Published: September 30, 2019
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: November 06, 2018
Last Updated: 09/26/2026